Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network

    March 2017 in “Contraception
    Lucía Cea Soriano, Alex Asiimwe, Luis A. García Rodríguez
    Image of study
    TLDR The medication cyproterone acetate/ethinylestradiol is usually prescribed correctly for acne after other treatments don't work.
    The retrospective study analyzed the prescribing patterns of cyproterone acetate/ethinylestradiol (CPA/EE) in the UK, using data from The Health Improvement Network and focusing on women who started CPA/EE in 2011 (N=2760), 2012 (N=2923), and 2014 (N=2341). It found that a majority of these women had a diagnosis of a hyperandrogenic condition, such as acne, and had previously received acne treatment, which aligns with the medication's approved indications. Rarely did these women use CPA/EE concurrently with another hormonal contraceptive, with rates of less than 0.5% in 2012 and 2014, and only 1% in 2011. The study concluded that CPA/EE is typically prescribed in accordance with guidelines, after other acne treatments have failed, and emphasized the value of free-text comments in patient records for providing additional diagnostic information. Despite potential limitations like misclassification and underrecording, the study's large sample size and validated data source support its findings.
    View this study on →